0001193125-22-121628.txt : 20220427 0001193125-22-121628.hdr.sgml : 20220427 20220427074756 ACCESSION NUMBER: 0001193125-22-121628 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220427 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220427 DATE AS OF CHANGE: 20220427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 22856392 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 8-K 1 d342731d8k.htm 8-K 8-K
REPLIGEN CORP false 0000730272 0000730272 2022-04-27 2022-04-27

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2022

 

 

REPLIGEN CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-14656   04-2729386

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453
(Address of principal executive offices, including zip code)

(781) 250-0111

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.01 per share   RGEN   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On April 27, 2022, Repligen Corporation announced its financial results for the first quarter ended March 31, 2022. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press Release by Repligen Corporation, dated April 27, 2022
104    Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REPLIGEN CORPORATION
Date: April 27, 2022   By:  

/s/ Tony J. Hunt

    Tony J. Hunt
    President and Chief Executive Officer
 EX-99.1 2 d342731dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

       

Repligen Corporation

41 Seyon Street

Building #1, Suite 100

Waltham, Massachusetts 02453

 

Repligen Reports First Quarter 2022 Financial Results

and Updates Full Year 2022 Financial Guidance

 

•  

Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency

 

•  

Organic revenue growth of 44% for the quarter and base business growth of 37%

 

•  

Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue

WALTHAM, Mass. – April 27, 2022 – Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2022. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2022 and access information for today’s webcast and conference call.

Tony J. Hunt, President and Chief Executive Officer said, “We delivered on another outstanding quarter for the company with over $206 million in revenue and 44% organic growth. We were especially pleased with the momentum in our base business, which delivered 37% growth in the quarter, led by impressive performance in our Filtration, Chromatography and Analytics businesses and strength in gene therapy revenue, which was up more than 100%. COVID-related programs accounted for 26% of our revenues in the first quarter. With slowing vaccination rates, we expect lower COVID-related demand and revenue this year, largely offset by increased projected demand for our base business products. Overall, our outlook for 2022 remains very positive; we have a strong order book coming out of the first quarter and are increasing our guidance for full year non-COVID business performance.”

Financial Highlights for the First Quarter 2022

 

  •  

Revenue increased by $63.6 million in the first quarter, or 45% year-over-year as reported, and 44% organically, to $206.4 million.

 

  •  

GAAP gross margin was 60.1%, an increase of 190 bps; Adjusted (non-GAAP) gross margin was 60.4%, an increase of 100 bps.

 

  •  

GAAP operating margin was 29.1%, an increase of 360 bps; Adjusted (non-GAAP) operating margin was 32.6%, an increase of 70 bps.

 

  •  

GAAP fully diluted EPS increased to $0.81 compared to $0.52 for the first quarter of 2021; Adjusted (non-GAAP) fully diluted EPS increased to $0.92 compared to $0.68 for the first quarter of 2021.

 

1

Financial Details for the First Quarter 2022

REVENUE

 

  •  

Total revenue for the first quarter of 2022 increased to $206.4 million compared to $142.8 million for the first quarter of 2021, a year-over-year gain of 45% as reported and 48% at constant currency, with organic growth of 44%.

REVENUE MIX

 

  •  

For the first quarter of 2022, our base business accounted for 71% of revenue, COVID-related sales accounted for 26% of revenue, and inorganic revenue from acquisitions made in 2021 accounted for 3% of revenue.

GROSS PROFIT and GROSS MARGIN

 

  •  

Gross profit (GAAP) for the first quarter of 2022 was $124.0 million, a year-over-year increase of $41.0 million. Adjusted gross profit (non-GAAP) for the first quarter of 2022 was $124.6 million, a year-over-year increase of $39.8 million.

 

  •  

Gross margin (GAAP) for the first quarter of 2022 was 60.1%, an increase from 58.2% for the first quarter of 2021. Adjusted gross margin (non-GAAP) for the first quarter was 60.4%, compared to 59.3% in the 2021 period.

OPERATING INCOME

 

  •  

Operating income (GAAP) for the first quarter of 2022 was $60.0 million, a year-over-year increase of $23.6 million.

 

  •  

Adjusted operating income (non-GAAP) for the first quarter of 2022 was $67.4 million, a year-over-year increase of $21.7 million, or 47%.

NET INCOME

 

  •  

Net income (GAAP) for the first quarter of 2022 increased to $47.0 million, a year-of-year increase of $17.5 million.

 

  •  

Adjusted net income (non-GAAP) for the first quarter of 2022 was $53.7 million, a year-over-year increase of $15.0 million, or 39%.

EARNINGS PER SHARE

 

  •  

Earnings per share (GAAP) for the first quarter of 2022 increased to $0.81 on a fully diluted basis, compared to $0.52 for the first quarter of 2021.

 

  •  

Adjusted EPS (non-GAAP) for the first quarter of 2022 increased to $0.92 on a fully diluted basis, compared to $0.68 for the 2021 period.

 

2

EBITDA

 

  •  

EBITDA, a non-GAAP financial measure, for the first quarter of 2022 increased to $71.4 million compared to $44.6 million for the first quarter of 2021.

 

  •  

Adjusted EBITDA for the first quarter of 2022 was $72.2 million, a year-over-year increase of $23.5 million, or 48%.

CASH

 

  •  

Our cash and cash equivalents at March 31, 2022 were $584.6 million, compared to $603.8 million at December 31, 2021.

All reconciliations of GAAP to adjusted (non-GAAP) figures above, as well as EBITDA to adjusted EBITDA, are detailed in the reconciliation tables included later in this press release.

Financial Guidance for 2022

Our financial guidance for the fiscal year 2022 is based on expectations for our existing business and includes the financial impact of our 2021 acquisitions of BioFlex Solutions (which closed on December 16, 2021), Avitide Inc. (which closed on September 20, 2021) and Polymem S.A. (which closed on July 1, 2021). The guidance below excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates.

FISCAL YEAR 2022 GUIDANCE:

 

  •  

Total revenue is expected to be in the range of $770-$800 million, a $30 million or approximate 4% reduction from our previous guidance of $800-$830 million. Our updated guidance reflects lower expected COVID-related demand, mainly in the second half of 2022, largely offset by increased projected demand for our base business products. Our base business revenue, which excludes inorganic acquisition revenue, is expected to increase by 24%-31%, an increase from our previous guidance of 20%-22%. We are now guiding to overall revenue growth of 15%-19% as reported, 17%-21% at constant currency, and organic growth of 14%-18%.

 

  •  

Gross margin is expected to be 57%-58% on both a GAAP and non-GAAP basis, consistent with our previous guidance.

 

  •  

Income from operations is expected to be in the range of $180-$186 million on a GAAP basis. Adjusted (non-GAAP) income from operations is expected to be in the range of $225-$231 million, compared to our previous guidance of $234-$240 million.

 

  •  

Net income is expected to be in the range of $139-$144 million on a GAAP basis. Adjusted (non-GAAP) net income is expected to be in the range of $177-$182 million, compared to our previous guidance of $185-$190 million. Our current guidance reflects a tax rate of 21% on adjusted pre-tax income.

 

3

  •  

Fully diluted GAAP EPS is expected to be in the range of $2.41-$2.49. Adjusted (non-GAAP) fully diluted EPS is expected to be in the range of $3.07-$3.15, compared to our previous guidance of $3.21-$3.30.

Our non-GAAP guidance for the fiscal year 2022 excludes the following items:

 

  •  

$13.7 million estimated acquisition and integration expenses; $1.3 million in cost of product revenue, $0.7 million in R&D and $11.6 million in SG&A.

 

  •  

$26.4 million estimated intangible amortization expense in SG&A.

 

  •  

$1.8 million of amortization of debt issuance (Other income (expense)).

 

  •  

$5.1 million estimated contingent consideration related to estimated time value of money impacts from our 2021 Avitide acquisition.

Our non-GAAP guidance for the fiscal year 2022 includes:

 

  •  

An income tax increase of $8.9 million, representing the tax impact on acquisition and integration costs, intangible amortization and contingent consideration, and amortization of debt issuance costs.

All reconciliations of GAAP to adjusted (non-GAAP) guidance are detailed in the tables included later in this press release.

Conference Call

Repligen will host a conference call and webcast today, April 27, 2022, at 8:30 a.m. EST, to discuss first quarter 2022 financial results and corporate developments. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 6956973.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: revenue growth rate at constant currency; adjusted gross profit and adjusted gross margin; adjusted income from operations; adjusted operating income and adjusted net income; earnings before interest, taxes, depreciation and amortization (EBITDA); adjusted EBITDA; adjusted net income; adjusted net income per share; adjusted earnings per diluted share (EPS); adjusted cost of sales; adjusted R&D expense; and adjusted SG&A. The Company provides organic revenue growth rates in constant currency to exclude the impact of both foreign currency translation, and the impact of acquisition revenue for current year periods that have no prior year comparable, in order to facilitate a comparison of its current revenue performance to its past revenue performance. The Company provides revenue growth rates in constant currency in order to

 

4

facilitate a comparison of its current revenue performance to its past revenue performance. To calculate revenue growth rates in constant currency, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period.

The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition related inventory step-up costs, acquisition and integration costs, intangible amortization costs, and contingent consideration expenses related to the Company’s acquisitions, amortization of debt issuance costs related to Company’s convertible debt, non-cash interest expense, loss on conversion of debt, and the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company’s operating performance and guidance investors should not consider non-GAAP measures as substitutable for the comparable financial measures prepared in accordance with GAAP.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, including cash and investment position, demand in the markets in which we operate, the expected performance of our business, the expected performance of our acquired BioFlex Solutions, Avitide Inc. and Polymem S.A. businesses our ability to continue to generate, and the magnitude of, COVID-related revenue, the expected performance and success of our strategic partnerships, management’s strategy, plans and objectives for future operations or acquisitions, product development and sales, selling, general and administrative expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources, our financing plans, and the projected impact of, and response to, the COVID-19 coronavirus pandemic on our business and on the U.S. and global economies constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” “projected,” “estimated” or “could” and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with the following: the effect of the COVID-19 coronavirus pandemic,

 

5

including mitigation efforts and economic effects, on our business operations and the operations of our customers and suppliers; the ultimate impact of the COVID-19 coronavirus pandemic on our business or financial results; our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate and acquired businesses, including the BioFlex Solutions, Avitide Inc. and Polymem S.A. businesses into our business and achieve the expected benefits of such acquisitions; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K for the year ended December 31, 2021 on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management’s current views, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information, future development or otherwise, that occur after the date hereof except as required by law.

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881

investors@repligen.com

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share data)

 

     Three Months Ended
March 31,		  
     2022     2021  

Revenue:

     

Product revenue

    $ 206,363     $ 142,737  

Royalty and other revenue

      37       100  
  

 

 

    

 

 

  

Total revenue

      206,400       142,837  

Costs and expenses:

     

Cost of product revenue

      82,356       59,747  

Research and development

      12,155       7,612  

Selling, general and administrative

      54,300       39,095  

Contingent consideration

      (2,411 )      —    
  

 

 

    

 

 

  
     146,400       106,454  
  

 

 

    

 

 

  

Income from operations

      60,000       36,383  

Investment income

      77       52  

Interest expense

      (292 )      (2,754 ) 

Amortization of debt issuance costs*

      (452 )      (352 ) 

Other expenses, net

      (402 )      (224 ) 
  

 

 

    

 

 

  

Income before income taxes

      58,931       33,105  

Income tax provision

      11,967       3,655  
  

 

 

    

 

 

  

Net income

    $ 46,964     $ 29,450  
  

 

 

    

 

 

  

Earnings per share:

     

Basic

    $ 0.85     $ 0.54  
  

 

 

    

 

 

  

Diluted*

    $ 0.81     $ 0.52  
  

 

 

    

 

 

  

Weighted average shares outstanding:

     

Basic

      55,352,886       54,805,051  
  

 

 

    

 

 

  

Diluted*

      58,816,354       56,868,793  
  

 

 

    

 

 

  

 

*

Under ASU 2020-06, the Company is required to reflect the dilutive effect of the 2019 Notes by application of the if-converted method. Prior to filing the Second Supplemental Indenture on March 4, 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the weighted average diluted EPS calculation. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion principal in cash and only the premium in shares of the Company’s common stock. Therefore, from March 5, 2022 to March 31, 2022 the Company included 980,525 shares in the denominatior of the weighted average diluted EPS cacluation. Under the if-converted method, the Company was also required to exclude amortization of debt issuance cost and interest charges applicable to the convertible debt from the numerator of the diluted EPS calculation for the period from January 1, 2022 to March 4, 2022, assuming the interest on convertible debt was never recognized for that period. For the three months ended March 31, 2022, the Company excluded amortization of debt issuance costs and interest charges for the period January 1, 2022 to March 4, 2022 of $0.4 million (tax effected) from the numerator.

 

Balance Sheet Data:    March 31,
2022		      December 31,
2021		  

Cash, cash equivalents and marketable securities

    $ 584,640      $ 603,814  

Working capital

      520,456        556,415  

Total assets

      2,383,824        2,358,354  

Long-term obligations*

      193,090        233,025  

Accumulated earnings

      258,277        194,060  

Stockholders’ equity

      1,766,401        1,750,067  

 

*

Includes long-term portion of the contingent consideration obligation related to the acquisition of Avitide Inc.

REPLIGEN CORPORATION

RECONCILIATION OF GAAP INCOME FROM OPERATIONS TO NON-GAAP (ADJUSTED) INCOME FROM OPERATIONS

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,		  
     2022      2021  

GAAP INCOME FROM OPERATIONS

    $ 60,000      $ 36,383  

ADJUSTMENTS TO INCOME FROM OPERATIONS:

      

Inventory step-up charges

      —          1,598  

Acquisition and integration costs

      3,189        2,551  

Contingent consideration

      (2,411 )       —    

Intangible amortization

      6,593        5,162  
  

 

 

     

 

 

  

ADJUSTED INCOME FROM OPERATIONS

    $ 67,371      $ 45,694  
  

 

 

     

 

 

  

REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) NET INCOME

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,		  
     2022      2021  

GAAP NET INCOME

    $ 46,964      $ 29,450  

ADJUSTMENTS TO NET INCOME:

      

Inventory step-up charges

      —          1,598  

Acquisition and integration costs

      3,189        2,551  

Contingent consideration

      (2,411 )       —    

Intangible amortization

      6,593        5,162  

Loss on conversion of debt

      —          1  

Amortization of debt issuance costs

      452        352  

Non-cash interest expense(1)

      —          2,476  

Tax effect of non-GAAP charges

      (1,042 )       (2,822 ) 
  

 

 

     

 

 

  

ADJUSTED NET INCOME

    $ 53,745      $ 38,768  
  

 

 

     

 

 

  

 

(1)

Includes impact from adoption of ASU 2020-06.

 

8

REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME PER SHARE TO NON-GAAP (ADJUSTED) NET INCOME PER SHARE

(Unaudited)

 

     Three Months Ended
March 31,		  
     2022      2021  

GAAP NET INCOME PER SHARE - DILUTED

    $ 0.81      $ 0.52  

ADJUSTMENTS TO NET INCOME PER SHARE - DILUTED:

      

Inventory step-up charges

      —          0.03  

Acquisition and integration costs

      0.05        0.04  

Contingent consideration

      (0.04 )       —    

Intangible amortization

      0.11        0.09  

Loss on conversion of debt

      —          0.00  

Amortization of debt issuance costs(1)

      0.00        0.01  

Non-cash interest expense(2)

      —          0.04  

Tax effect of non-GAAP charges

      (0.02 )       (0.05 ) 
  

 

 

     

 

 

  

ADJUSTED NET INCOME PER SHARE - DILUTED

    $ 0.92      $ 0.68  
  

 

 

     

 

 

  

 

(1)

Represents amortization of debt issuance costs for the period March 5, 2022 to March 31, 2022 after the Second Supplemental Indenture was filed. Debt issuance cost for the period January 1, 2022 to March 4, 2022 are already reflected in the GAAP net income per share - diluted EPS under the if-converted method of calculating diluted EPS.

(2)

Includes impact from adoption of ASU 2020-06.

Totals may not add due to rounding.

REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET

INCOME TO ADJUSTED EBITDA

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,		  
     2022      2021  

GAAP NET INCOME

    $ 46,964      $ 29,450  

ADJUSTMENTS:

      

Investment income

      (77 )       (52 ) 

Interest expense

      292        277  

Non-cash interest expense(1)

      —          2,477  

Amortization of debt issuance costs

      452        352  

Income tax provision

      11,967        3,655  

Depreciation

      5,213        3,255  

Amortization(2)

      6,621        5,189  
  

 

 

     

 

 

  

EBITDA

      71,432        44,603  

OTHER ADJUSTMENTS:

      

Inventory step-up charges

      —          1,598  

Acquisition and integration costs

      3,189        2,551  

Contingent consideration

      (2,411 )       —    

Loss on conversion of debt

      —          1  
  

 

 

     

 

 

  

ADJUSTED EBITDA

    $ 72,210      $ 48,753  
  

 

 

     

 

 

  

 

(1)

Includes impact from adoption of ASU 2020-06.

(2)

Includes amortization of milestone payments in accordance with GAAP of $27 for each period presented.

 

9

REPLIGEN CORPORATION

RECONCILIATION OF GAAP COST OF SALES TO NON-GAAP (ADJUSTED) COST OF SALES

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,		  
     2022      2021  

GAAP COST OF SALES

    $ 82,356      $ 59,747  

ADJUSTMENT TO COST OF SALES:

      

Inventory step-up charges

      —          (1,598 ) 

Acquisition and integration costs

      (527 )       (81 ) 
  

 

 

     

 

 

  

ADJUSTED COST OF SALES

    $ 81,829      $ 58,068  
  

 

 

     

 

 

  

REPLIGEN CORPORATION

RECONCILIATION OF GAAP R&D EXPENSE TO NON-GAAP (ADJUSTED) R&D EXPENSE

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,		  
     2022      2021  

GAAP R&D

    $ 12,155      $ 7,612  

ADJUSTMENT TO R&D:

      

Acquisition and integration costs

      (317 )       (220 ) 
  

 

 

     

 

 

  

ADJUSTED R&D

    $ 11,838      $ 7,392  
  

 

 

     

 

 

  

REPLIGEN CORPORATION

RECONCILIATION OF GAAP SG&A EXPENSE TO NON-GAAP (ADJUSTED) SG&A EXPENSE

(Unaudited, amounts in thousands)

 

     Three Months Ended
March 31,		  
     2022      2021  

GAAP SG&A EXPENSE

    $ 54,300      $ 39,095  

ADJUSTMENTS TO SG&A EXPENSE:

      

Acquisition and integration costs

      (2,345 )       (2,250 ) 

Intangible amortization

      (6,593 )       (5,162 ) 
  

 

 

     

 

 

  

ADJUSTED SG&A EXPENSE

    $ 45,362      $ 31,683  
  

 

 

     

 

 

  

 

10

REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME GUIDANCE TO ADJUSTED (NON-GAAP NET INCOME GUIDANCE)

 

(in thousands)    Twelve months ending December 31, 2022  
     Low End      High End  

GUIDANCE ON NET INCOME

    $ 139,000      $ 144,000  

ADJUSTMENTS TO GUIDANCE ON NET INCOME:

      

Acquisition and integration costs

      13,690        13,690  

Anticipated pre-tax amortization of acquisition-related intangible assets

      26,382        26,382  

Amortization of debt issuance costs

      1,808        1,808  

Contingent consideration

      5,089        5,089  

Tax effect of intangible amortization and integration

      (8,874 )       (8,874 ) 

Guidance rounding adjustment

      (95 )       (95 ) 
  

 

 

     

 

 

  

GUIDANCE ON ADJUSTED NET INCOME

    $ 177,000      $ 182,000  
  

 

 

     

 

 

  

Totals may not add due to rounding.

REPLIGEN CORPORATION

RECONCILIATION OF GAAP NET INCOME PER SHARE GUIDANCE TO

ADJUSTED (NON-GAAP) NET INCOME PER SHARE GUIDANCE

 

     Twelve months ending December 31, 2022  
     Low End      High End  

GUIDANCE ON NET INCOME PER SHARE - DILUTED

    $ 2.41      $ 2.49  

ADJUSTMENTS TO GUIDANCE ON NET INCOME PER SHARE - DILUTED:

      

Acquisition and integration costs

    $ 0.24      $ 0.24  

Anticipated pre-tax amortization of acquisition-related intangible assets

    $ 0.46      $ 0.46  

Amortization of debt issuance costs

    $ 0.03      $ 0.03  

Contingent consideration

    $ 0.09      $ 0.09  

Tax effect of intangible amortization and integration

    ($ 0.15 )     ($ 0.15 ) 

Guidance rounding adjustment

    ($ 0.00 )     ($ 0.00 ) 
  

 

 

     

 

 

  

GUIDANCE ON ADJUSTED NET INCOME PER SHARE - DILUTED

    $ 3.07      $ 3.15  
  

 

 

     

 

 

  

Totals may not add due to rounding.

# # #

 

 

11

EX-101.SCH 3 rgen-20220427.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rgen-20220427_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rgen-20220427_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g342731g0427034329493.jpg GRAPHIC begin 644 g342731g0427034329493.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 27, 2022
Cover [Abstract]  
Entity Registrant Name REPLIGEN CORP
Amendment Flag false
Entity Central Index Key 0000730272
Document Type 8-K
Document Period End Date Apr. 27, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-14656
Entity Tax Identification Number 04-2729386
Entity Address, Address Line One 41 Seyon Street
Entity Address, Address Line Two Bldg. 1
Entity Address, Address Line Three Suite 100
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02453
City Area Code (781)
Local Phone Number 250-0111
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol RGEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d342731d8k_htm.xml IDEA: XBRL DOCUMENT 0000730272 2022-04-27 2022-04-27 REPLIGEN CORP false 0000730272 8-K 2022-04-27 DE 001-14656 04-2729386 41 Seyon Street Bldg. 1 Suite 100 Waltham MA 02453 (781) 250-0111 false false false false Common Stock, par value $0.01 per share RGEN NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G MH_ 0 / ( \ !X;"]W;W)K8F]O M:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$ MQJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW M ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]& MA!1ZE@MAA92XW^CYC6@\@2P/73>TFH=>Y!L/?P M&HT=S8\?M_P!4$L#!!0 ( /L]FU0D'INBK0 /@! : >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S M(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[. MXS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " #[/9M499!YDAD! #/ P $P %M# M;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK M_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBN MM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F MI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S! M9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8 MYL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( /L]FU0' M04UB@0 +$ 0 " 0 !D;V-0&UL M4$L! A0#% @ ^SV;5&N\%.;O *P( !$ ( !KP M &1O8U!R;W!S+V-O&UL4$L! A0#% @ ^SV;5)E&PO=V]R M:W-H965T&UL4$L! A0#% @ ^SV;5)^@&_"Q @ X@P M T ( !F0P 'AL+W-T>6QE$ M>&PO=V]R:V)O;VLN>&UL4$L! A0#% @ ^SV;5"0>FZ*M ^ $ !H M ( !RA$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !KQ( %M# G;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ ^1, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d342731d8k.htm d342731dex991.htm rgen-20220427.xsd rgen-20220427_lab.xml rgen-20220427_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d342731d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d342731d8k.htm" ] }, "labelLink": { "local": [ "rgen-20220427_lab.xml" ] }, "presentationLink": { "local": [ "rgen-20220427_pre.xml" ] }, "schema": { "local": [ "rgen-20220427.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rgen", "nsuri": "http://www.repligencorp.com/20220427", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d342731d8k.htm", "contextRef": "duration_2022-04-27_to_2022-04-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d342731d8k.htm", "contextRef": "duration_2022-04-27_to_2022-04-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.repligencorp.com//20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-121628-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-121628-xbrl.zip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end